Clinical trials: Dalteparin
Nephrotic Syndrome
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
The primary objective is to test the hypothesis that enoxaparin efficacy is reduced in severe nephrotic syndrome. Another purpose is to compare two dosing regimens.
- Trial name
- ENOX-inNS (NCT04558892)
- Testing
- Enoxaparin
- Where
- Poland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Military Institute od Medicine National Research Institute
Venous Thromboembolism, Lung Neoplasms
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
After any surgery, there is a risk of venous thromboembolism (VTE), including Deep Vein Thrombosis (DVT) in the major veins of the legs and Pulmonary Embolus (PE) in the lungs.
- Conditions
- Venous Thromboembolism, Lung Neoplasms, Pulmonary Embolism
- Trial name
- NCT02334007
- Testing
- LMWH: Dalteparin
- Where
- 2 sites in Canada
- Volunteers
- 102 people
- Sponsor
- McMaster University
Myeloma, Venous Thromboembolism
Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
To evaluate: the incidence of venous thromboembolic event (VTE) the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an…
- Trial name
- MYELAXAT (NCT02066454)
- Testing
- Apixaban
- Where
- 19 sites in France
- Volunteers
- 108 people
- Sponsor
- University Hospital, Grenoble
Unfractionated Heparin Treatment
Evaluation of the Effect of Dextran Sulphate on Anti-Xa Activities Measured
The measurement of anti-Xa activity is classically used for the dose adjustement of unfractionated heparin (UFH) treatment and to monitor reversal of UFH by protamine during cardiac surgery with cardiopulmonary bypass (CPB).
- Trial name
- DEXHEP (NCT04700670)
- Testing
- measurement of anti-Xa activities
- Where
- 8 sites in France
- Volunteers
- 164 people
- Sponsor
- Rennes University Hospital
Infertility
Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI)
Heparin also has the ability to bind with and modulate a wide variety of proteins, which can influence a number of physiological processes involved in implantation \& trophoblastic development.
- Trial name
- NCT02325479
- Testing
- Enaoxaprin sodium, tissue culture media
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Egyptian IVF-ET Center
Abortion, Habitual
Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss
With this clinical trial the investigators will analyze whether the rate of pregnancy losses before the 24th week of gestation can be reduced by dalteparin treatment in habitual aborters.
- Trial name
- NCT00400387
- Testing
- Fragmin P Forte (dalteparin sodium), Multivitamin supplement
- Where
- 12 sites in Austria, Germany
- Volunteers
- 449 people
- Sponsor
- University of Jena
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- ASTER (NCT05171049)
- Testing
- Abelacimab, Apixaban
- Where
- 209 sites in United States, Australia and 19 more
- Volunteers
- 1,150 people
- Sponsor
- Anthos Therapeutics, Inc.
Recurrent Pregnancy Loss, Antiphospholipid Antibody Syndrome
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.
- Trial name
- HepASA (NCT00564174)
- Testing
- Low molecular weight heparin and low dose aspirin, Low dose aspirin
- Where
- 2 sites in Canada
- Volunteers
- 88 people
- Sponsor
- Mount Sinai Hospital, Canada
Total Knee Arthroplasty, Venous Thromboembolism
Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Yes. For these two fields, I would enter the following in English, based on your study protocol. 1. Brief Summary Copy and paste: This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total…
- Trial name
- DOLOTHROK (NCT07869615)
- Testing
- Apixaban, Rivaroxaban, Enoxaparin (LMWH)
- Where
- Tunisia
- Volunteers
- 138 people
- Sponsor
- Military Hospital of Tunis
Venous Thromboembolism (VTE), Trauma Related Injuries
Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial
This multicentre pilot trial will assess the feasibility of a full-scale, randomized trial to determine whether bloodwork guided dosing of blood thinners reduces the risk of clotting in high-risk trauma patients.
- Trial name
- PrOVE iT (NCT06662253)
- Testing
- Anti-Xa Guided Dosing of Low Molecular Weight Heparin, Standard of Care Dosing
- Volunteers
- 150 people
- Sponsor
- Alexandre Tran
Deep-Venous Thrombosis, Pulmonary Embolism
Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin
The purpose of this study is to determine if fixed dose heparin infusions at a rate of 500 units/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for venous thromboembolism (VTE) prophylaxis in patients…
- Conditions
- Deep-Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- NCT02970032
- Testing
- Real time heparin dose adjustment, Standard heparin dose
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Epithelial Ovarian Cancer
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Background: Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant.
- Trial name
- NCT05284552
- Testing
- Tinzaparin Injectable Solution
- Where
- 8 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- University Hospital, Linkoeping
Venous Thromboembolism, Obese Patients
Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.
To evaluate appropriateness of enoxaparin bioavailability at two different sites of subcutaneous administration (arms or abdomen) in primary or secondary prevention of thromboembolism in a population of patients with severe…
- Trial name
- EPOS (NCT07213713)
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cardiac Surgery With Cardiopulmonary Bypass
Systematic Evaluation of Protamine Doze in Cardiac Surgery
The precise amount of protamine required to neutralize unfractionated heparin (UFH) remains unknown. This study will systematically identify the doze needed to neutralize UFH following cardiopulmonary bypass (CPB).
- Trial name
- HART (NCT03787641)
- Testing
- Protamine Sulfate
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Deep Vein Thrombosis, Inflammatory Response
Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis
Anticoagulants influence either coagulation, inflammation and inflammatory processes in deep vein thrombosis (DVT). Acute DVT cause an inflammatory response that may persist for a long period of time.
- Trial name
- Aticks Live (NCT04741464)
- Testing
- Tinzaparin
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Deep-Vein Thrombosis
Treatment of Upper Extremity Deep-Vein Thrombosis
The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.
- Trial name
- NCT00245856
- Testing
- Dalteparin sodium injection, Warfarin
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- University of Oklahoma
Deep Vein Thrombosis
The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section
Venous thromboembolism (VTE) remains the most common cause of maternal death in the developed world. VTE includes two conditions, deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Trial name
- NCT00225108
- Testing
- Tinzaparin
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
The purpose of this study is to evaluate whether the effect of the two new anticoagulants, Dabigatran and Rivaroxaban, can be reversed by non-specific and specific inhibitors.
- Trial name
- REVNEWANTICO (NCT01210755)
- Testing
- Rivaroxaban, Dabigatran, Dabigatran; Rivaroxaban
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
COVID, Pneumonia, Viral
High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy
Randomized, controlled study conducted in hospitalized patients with severe COViD-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation.
- Conditions
- COVID, Pneumonia, Viral, Coagulation Disorder
- Trial name
- COVID-19 HD (NCT04408235)
- Testing
- Enoxaparin
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Critically Ill, Anti-Xa
Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China
Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin（LMWH）, many patients still develop life-threatening embolism.
- Trial name
- NCT03311984
- Testing
- anti Xa level
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Southeast University, China